Table 3:

Quantitative benchmarks for clinical practice management

Characteristic	Value (%) [95% CI]
Percentage of initial BI-RADS 3 to total screens	1,037/135,765 (0.76%) [ 0.72% - 0.81%]
Percentage of initial BI-RADS 3 to screen-recalled (BI-RADS 0) cases	1,037/13,453 (7.71%) [7.26% - 8.17%]
Upgrade rate within 24 months of BI-RADS 3	77/1,037 (7.43%) [5.90% - 9.19%]
PPV3 of biopsies within 24 months of BI-RADS 3	26/77 (33.77%) [23.38% - 45.45%]
Cancer yield within 24 months of BI-RADS 3	26/1,037 (2.51%) [1.64% - 3.65%]
Cancer type
Ductal carcinoma in situ (DCIS)	12/26 (46.2%) [26.6% - 66.6%]
Invasive ductal carcinoma (IDC)	11/26 (42.3%) [23.4% - 63.1%]
Invasive lobular carcinoma (ILC)	3/26 (11.5%) [2.5% - 30.2%]